Clinical Trial End Points and Guidelines Recommendations

Panelists reflect on how overall survival and progression-free survival inform the evaluation of new therapies. They note that survival benefit remains the gold standard for demonstrating meaningful clinical impact, but progression-free data can offer early insight into efficacy trends. Recent updates to major guidelines have integrated these findings, helping clinicians align practice with the strongest available evidence.

The discussion emphasizes that national recommendations provide a valuable framework, particularly for practitioners in community settings. However, panelists caution that guidelines should serve as a foundation—not a substitute—for individualized clinical judgment. Patient preference, comorbidities, and local resource availability must still inform every treatment plan.

By balancing evidence-based standards with practical realities, clinicians can ensure that patients receive consistent, effective, and equitable care across diverse practice environments.